CompletedPhase 2NCT04175522
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
Studying Autoimmune encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Green Cross Corporation
- Principal Investigator
- Soon Tae Lee, MD, Ph.D.Seoul National University Hospital
- Intervention
- Immunoglobulin G(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2019 – 2020
Study locations (1)
- Seoul National University Hospital, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04175522 on ClinicalTrials.govOther trials for Autoimmune encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07158229Long-term Impact of NMDAR Encephalitis, Level 3Hospices Civils de Lyon
- RECRUITINGNCT07477015Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune EncephalitisFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT06867991Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisThe First People's Hospital of Changzhou
- RECRUITINGNANCT06584045Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)Tongji Hospital
- RECRUITINGNCT07133113Medium-term Effects of Treatments in Autoimmune EncephalitisHospices Civils de Lyon
- RECRUITINGNCT06019975FDG-PET in the Diagnosis of Autoimmune EncephalitisUniversity of Milano Bicocca
- RECRUITINGPHASE3NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisHoffmann-La Roche
- ACTIVE NOT RECRUITINGNCT07145502Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory SyndromesBiocells Medical